Integer Holdings Corp is a medical devices business based in the US. Integer shares (ITGR) are listed on the NYSE and all prices are listed in US Dollars. Integer employs 9,000 staff and has a trailing 12-month revenue of around $1.3 billion.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $62.87 |
|---|---|
| 52-week range | $59.18 - $95.73 |
| 50-day moving average | $67.47 |
| 200-day moving average | $75.86 |
| Wall St. target price | $104.33 |
| PE ratio | 27.52 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $2.25 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $62.87 from 2022-09-29
| 1 week (2022-09-23) | 1.53% |
|---|---|
| 1 month (2022-09-01) | 0.91% |
| 3 months (2022-07-01) | -12.68% |
| 6 months (2022-04-01) | -23.82% |
| 1 year (2021-10-01) | -31.75% |
|---|---|
| 2 years (2020-10-01) | 8.10% |
| 3 years (2019-10-01) | 73.55 |
| 5 years (2017-09-29) | 22.91% |
Valuing Integer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Integer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Integer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, Integer shares trade at around 28x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Integer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.63. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Integer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Integer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $218.5 million.
The EBITDA is a measure of a Integer's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.3 billion |
|---|---|
| Operating margin TTM | 10.3% |
| Gross profit TTM | $337 million |
| Return on assets TTM | 3.22% |
| Return on equity TTM | 5.55% |
| Profit margin | 6.1% |
| Book value | $41.17 |
| Market capitalisation | $2.1 billion |
TTM: trailing 12 months
We're not expecting Integer to pay a dividend over the next 12 months.
Over the last 12 months, Integer's shares have ranged in value from as little as $59.18 up to $95.73. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Integer's is 1.2253. This would suggest that Integer's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.